European Organisation For Research & Treatment Of Cancer

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.eortc.be

Clinical Trials

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Phase 1

Not yet recruiting

Conditions: GastroEsophageal Cancer

Interventions: Drug: Bemarituzumab

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-18

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 27

Registration Number: NCT06978062

Vorasidenib Maintenance for IDH Mutant Astrocytoma

Phase 3

Not yet recruiting

Conditions: IDH-mutant Grade 2 or 3 Astrocytoma

Interventions: Drug: Vorasidenib
Drug: Vorasidenib Placebo

First Posted Date: 2025-02-05

Last Posted Date: 2025-05-01

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 468

Registration Number: NCT06809322

Locations: 🇬🇧
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
🇦🇹
Kepler University Hospital - Neuromed campus, Linz, Austria
🇧🇪
U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium

and more 30 locations

Radiopharmaceutical Treatment of Advanced Kidney Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Clear Cell Renal Cell Carcinoma

Interventions: Drug: 177Lu-PSMA-617

First Posted Date: 2025-01-20

Last Posted Date: 2025-01-23

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 48

Registration Number: NCT06783348

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

Not Applicable

Not yet recruiting

Conditions: Colorectal Cancer
Prostate Cancer
Oligometastatic Disease
Breast Cancer
NSCLC

Interventions: Radiation: multiple-fraction SBRT
Radiation: single-fraction SBRT

First Posted Date: 2024-06-17

Last Posted Date: 2025-02-26

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 302

Registration Number: NCT06462963

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer

Phase 3

Not yet recruiting

Conditions: ER+ Breast Cancer
HER2-negative Breast Cancer
Breast Cancer Stage III
Breast Cancer Stage I
Drug-Related Side Effects and Adverse Reactions
Musculoskeletal Pain
Breast Cancer Stage II

Interventions: Behavioral: Booklet for healthy behaviors
Drug: Duloxetine 60 MG
Drug: Furosemide 40 mg

First Posted Date: 2024-05-09

Last Posted Date: 2024-11-05

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 399

Registration Number: NCT06407401

Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study

Not Applicable

Not yet recruiting

Conditions: Head and Neck Neoplasms

Interventions: Procedure: Early palliative care, integrated with the standard oncologic care (proactive approach)
Procedure: Palliative care requested as needed, integrated with the standard oncologic care (reactive approach)

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 160

Registration Number: NCT06347185

177Lu-DOTATATE for Recurrent Meningioma

Phase 2

Recruiting

Conditions: Recurrent Meningioma

Interventions: Drug: 177Lu-DOTATATE
Drug: Local standard of Care

First Posted Date: 2024-03-22

Last Posted Date: 2025-05-21

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 135

Registration Number: NCT06326190

Locations: 🇫🇷
CHRU de Nancy - Hopitaux De Brabois, Vandoeuvre Les Nancy, France
🇫🇷
Centre Leon Berard, Lyon, France
🇦🇹
Universitaetskliniken der Uni Wien - Universitaetsklinikum Wien - AKH unikliniken, Vienna, Austria

and more 2 locations

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Phase 2

Not yet recruiting

Conditions: Bladder Cancer

Interventions: Radiation: radiation therapy

First Posted Date: 2024-03-15

Last Posted Date: 2024-07-22

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 50

Registration Number: NCT06310369

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Phase 3

Recruiting

Conditions: Uveal Melanoma

Interventions: Drug: Tebentafusp

First Posted Date: 2024-02-07

Last Posted Date: 2025-05-01

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 290

Registration Number: NCT06246149

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇫🇷
Institut Curie - Hôpital de Paris, Paris, France
🇩🇪
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany

and more 3 locations

Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC

Phase 2

Recruiting

Conditions: NSCLC Stage IV

Interventions: Drug: Placebo
Drug: Cemiplimab

First Posted Date: 2024-01-23

Last Posted Date: 2025-02-03

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 136

Registration Number: NCT06219317

Locations: 🇮🇹
Fondazione IRCCS - Policlinico San Matteo, Pavia, Italy
🇮🇹
AUSL Della Romagna - Ospedale Santa Maria delle Croci, Ravenna, Italy
🇮🇹
Istituto Clinico Humanitas, Rozzano, Italy

and more 14 locations

Home Terms & Conditions Privacy Policy